<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35306427</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0023</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>153</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cytokine</Title>
          <ISOAbbreviation>Cytokine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Group 3 innate lymphocytes (ILC3s) upregulate IL-22 in response to elevated intracellular cAMP levels.</ArticleTitle>
        <Pagination>
          <StartPage>155862</StartPage>
          <MedlinePgn>155862</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cyto.2022.155862</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1043-4666(22)00071-0</ELocationID>
        <Abstract>
          <AbstractText>Group 3 innate lymphocytes (ILC3s) are important immune cells within mucosal tissues and protect against bacterial infections. They can be activated in response to the innate cytokines IL-23 or IL-1β, which rapidly increases their production of effector molecules that regulate barrier functions. Pathogens can subvert these anti-bacterial effects to evade mucosal defenses to infect the host. Bacillus anthracis, the causative agent of anthrax, produces two major toxins that can modulate the immune response. We have previously shown that lethal toxin downmodulates the function of ILC3s. On the other hand, edema toxin has been shown promote T helper 17 (Th17) cell differentiation, adaptive counterparts of ILC3s, via elevation of cyclic adenosine monophosphate (cAMP). We hypothesized that edema toxin may also modulate ILC3 function. In this study, we show that edema toxin has the opposite effect of lethal toxin; edema toxin directly activates ILC3s independently of innate cytokine stimulation. Treatment of a mouse ILC3-like cell line with edema toxin, a potent adenylate cyclase, upregulated production of the cytokine IL-22, a major effector molecule of ILC3s and a critical factor in maintaining mucosal barriers. Forskolin treatment phenocopied the effect observed with edema toxin and led to an increase in CREB phosphorylation in ILC3s. This observation has potential implications for a role for cAMP signaling in the activation of ILC3s.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sah</LastName>
            <ForeName>Prakash</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Derouen</LastName>
            <ForeName>Jonathan T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alexander</LastName>
            <ForeName>Justine L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zenewicz</LastName>
            <ForeName>Lauren A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Electronic address: lauren-zenewicz@ouhsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P20 GM103447</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P20 GM134973</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA225520</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U19 AI062629</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cytokine</MedlineTA>
        <NlmUniqueID>9005353</NlmUniqueID>
        <ISSNLinking>1043-4666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001427">Bacterial Toxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XEO71E2E45</RegistryNumber>
          <NameOfSubstance UI="C415368">interleukin-22</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001427" MajorTopicYN="Y">Bacterial Toxins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anthrax</Keyword>
        <Keyword MajorTopicYN="N">Bacterial toxins</Keyword>
        <Keyword MajorTopicYN="N">CAMP signaling</Keyword>
        <Keyword MajorTopicYN="N">CREB</Keyword>
        <Keyword MajorTopicYN="N">IL-22</Keyword>
        <Keyword MajorTopicYN="N">Innate lymphocyte</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35306427</ArticleId>
        <ArticleId IdType="mid">NIHMS1790487</ArticleId>
        <ArticleId IdType="pmc">PMC9010362</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cyto.2022.155862</ArticleId>
        <ArticleId IdType="pii">S1043-4666(22)00071-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eberl G, Colonna M, Di Santo JP, McKenzie AN, Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology, Science
348(6237) (2015) aaa6566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5658207</ArticleId>
            <ArticleId IdType="pubmed">25999512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panda SK, Colonna M, Innate Lymphoid Cells in Mucosal Immunity, Front Immunol
10 (2019) 861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6515929</ArticleId>
            <ArticleId IdType="pubmed">31134050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, Spits H, Innate Lymphoid Cells: 10 Years On, Cell
174(5) (2018) 1054–1066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klose CSN, Artis D, Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity, Cell Res
30(6) (2020) 475–491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7264134</ArticleId>
            <ArticleId IdType="pubmed">32376911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keir M, Yi Y, Lu T, Ghilardi N, The role of IL-22 in intestinal health and disease, J Exp Med
217(3) (2020) e20192195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7062536</ArticleId>
            <ArticleId IdType="pubmed">32997932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, van der Goot FG, The bacterial toxin toolkit, Nat Rev Mol Cell Biol
2(7) (2001) 530–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11433367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moayeri M, Leppla SH, Vrentas C, Pomerantsev AP, Liu S, Anthrax Pathogenesis, Annu Rev Microbiol
69 (2015) 185–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26195305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leppla SH, Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells, Proc Natl Acad Sci U S A
79(10) (1982) 3162–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC346374</ArticleId>
            <ArticleId IdType="pubmed">6285339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friebe S, van der Goot FG, Burgi J, The Ins and Outs of Anthrax Toxin, Toxins (Basel)
8(3) (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4810214</ArticleId>
            <ArticleId IdType="pubmed">26978402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottle M, Dove S, Seifert R, Bacillus anthracis edema factor substrate specificity: evidence for new modes of action, Toxins (Basel)
4(7) (2012) 505–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3407890</ArticleId>
            <ArticleId IdType="pubmed">22852066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paccani SR, Baldari CT, T cell targeting by anthrax toxins: two faces of the same coin, Toxins (Basel)
3(6) (2011) 660–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3202842</ArticleId>
            <ArticleId IdType="pubmed">22069732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seshadri S, Allan DSJ, Carlyle JR, Zenewicz LA, Bacillus anthracis lethal toxin negatively modulates ILC3 function through perturbation of IL-23-mediated MAPK signaling, PLoS Pathog
13(10) (2017) e1006690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5695638</ArticleId>
            <ArticleId IdType="pubmed">29059238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paccani SR, Benagiano M, Savino MT, Finetti F, Tonello F, D’Elios MM, Baldari CT, The adenylate cyclase toxin of Bacillus anthracis is a potent promoter of T(H)17 cell development, J Allergy Clin Immunol
127(6) (2011) 1635–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21310477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi Paccani S, Benagiano M, Capitani N, Zornetta I, Ladant D, Montecucco C, D’Elios MM, Baldari CT, The adenylate cyclase toxins of Bacillus anthracis and Bordetella pertussis promote Th2 cell development by shaping T cell antigen receptor signaling, PLoS Pathog
5(3) (2009) e1000325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2643477</ArticleId>
            <ArticleId IdType="pubmed">19266022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, Kastelein RA, Cua DJ, de Waal Malefyt R, Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling, J Exp Med
206(3) (2009) 535–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699124</ArticleId>
            <ArticleId IdType="pubmed">19273625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gold KN, Weyand CM, Goronzy JJ, Modulation of helper T cell function by prostaglandins, Arthritis Rheum
37(6) (1994) 925–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8003066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalinski P, Regulation of immune responses by prostaglandin E2, J Immunol
188(1) (2012) 21–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3249979</ArticleId>
            <ArticleId IdType="pubmed">22187483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robb CT, McSorley HJ, Lee J, Aoki T, Yu C, Crittenden S, Astier A, Felton JM, Parkinson N, Ayele A, Breyer RM, Anderton SM, Narumiya S, Rossi AG, Howie SE, Guttman-Yassky E, Weller RB, Yao C, Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis, J Allergy Clin Immunol
141(1) (2018) 152–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5626002</ArticleId>
            <ArticleId IdType="pubmed">28583370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allan DS, Kirkham CL, Aguilar OA, Qu LC, Chen P, Fine JH, Serra P, Awong G, Gommerman JL, Zuniga-Pflucker JC, Carlyle JR, An in vitro model of innate lymphoid cell function and differentiation, Mucosal Immunol
8(2) (2015) 340–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25138665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seamon KB, Daly JW, Forskolin: a unique diterpene activator of cyclic AMP-generating systems, J Cyclic Nucleotide Res
7(4) (1981) 201–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6278005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sassone-Corsi P, The cyclic AMP pathway, Cold Spring Harb Perspect Biol
4(12) (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3504441</ArticleId>
            <ArticleId IdType="pubmed">23209152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duverger A, Jackson RJ, van Ginkel FW, Fischer R, Tafaro A, Leppla SH, Fujihashi K, Kiyono H, McGhee JR, Boyaka PN, Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens, J Immunol
176(3) (2006) 1776–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16424208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hormozi K, Parton R, Coote J, Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice, FEMS Immunol Med Microbiol
23(4) (1999) 273–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10225286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quesnel-Hellmann A, Cleret A, Vidal DR, Tournier JN, Evidence for adjuvanticity of anthrax edema toxin, Vaccine
24(6) (2006) 699–702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16168529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duffin R, O’Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, Robb CT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM, Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE, Rossi AG, Yao C, Prostaglandin E(2) constrains systemic inflammation through an innate lymphoid cell-IL-22 axis, Science
351(6279) (2016) 1333–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4841390</ArticleId>
            <ArticleId IdType="pubmed">26989254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Avondt K, van Sorge NM, Meyaard L, Bacterial immune evasion through manipulation of host inhibitory immune signaling, PLoS Pathog
11(3) (2015) e1004644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4351076</ArticleId>
            <ArticleId IdType="pubmed">25742647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rougeaux C, Becher F, Ezan E, Tournier JN, Goossens PL, In vivo dynamics of active edema and lethal factors during anthrax, Sci Rep
6 (2016) 23346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4800402</ArticleId>
            <ArticleId IdType="pubmed">26996161</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
